Cedric Bisson

Grand Challenges Canada is dedicated to supporting Bold Ideas with Big Impact®. Funded by the Government of Canada and other partners, Grand Challenges Canada funds innovators in low- and middle-income countries and Canada. The bold ideas Grand Challenges Canada supports integrate science and technology, social and business innovation – known as Integrated Innovation®. One of the largest impact-first investors in Canada, and with a feminist investment approach, Grand Challenges Canada has supported a pipeline of over 800 innovations in more than 80 countries. Grand Challenges Canada estimates that these innovations have the potential to save up to 1 million lives and improve up to 28 million lives by 2030. For more information, visit www.grandchallenges.ca follow us on Twitter @GChallenges and on Facebook at https://www.facebook.com/grandchallengescanada/

BaroSense Inc. is a medical device company headquartered in Redwood City, CA, that focuses on the research and development of innovative, minimally invasive medical devices for the treatment of obesity. BaroSense is committed to the development of minimally invasive therapeutic weight loss procedures and devices. These innovative procedures and devices are intended to provide a meaningful contribution to those seeking to improve health status by losing excess weight. The BaroSense products and procedures create a safe, simple, effective and reversible alternative to the surgical treatment of obesity. BaroSense offers a less invasive approach to assist those people who want to get more out of lifestyle change programs, and who wish to avoid extensive and irreversible surgical procedures.

Mimetogen Pharmaceuticals Inc. is a pharmaceuticals company based out of 1000 de La Gauchetiare Street West, Suite 900, Quebec, Montreal, Quebec, Canada.

Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

Grand Challenges Canada is dedicated to supporting Bold Ideas with Big Impact®. Funded by the Government of Canada and other partners, Grand Challenges Canada funds innovators in low- and middle-income countries and Canada. The bold ideas Grand Challenges Canada supports integrate science and technology, social and business innovation – known as Integrated Innovation®. One of the largest impact-first investors in Canada, and with a feminist investment approach, Grand Challenges Canada has supported a pipeline of over 800 innovations in more than 80 countries. Grand Challenges Canada estimates that these innovations have the potential to save up to 1 million lives and improve up to 28 million lives by 2030. For more information, visit www.grandchallenges.ca follow us on Twitter @GChallenges and on Facebook at https://www.facebook.com/grandchallengescanada/

Teralys Capital is a technology-focused Fund of funds which finances private venture capital funds investing in life sciences, information technology and cleantech companies. With more than $2 billion in assets under management across four recent venture capital fund-of-funds, Teralys is the largest innovation focused investor in Canada with aggregate exposure to more than 60 funds and 700 companies. Our partner funds cover the entire investment spectrum from early stage start-ups to expansion, growth and technology buy-outs.

BaroSense Inc. is a medical device company headquartered in Redwood City, CA, that focuses on the research and development of innovative, minimally invasive medical devices for the treatment of obesity. BaroSense is committed to the development of minimally invasive therapeutic weight loss procedures and devices. These innovative procedures and devices are intended to provide a meaningful contribution to those seeking to improve health status by losing excess weight. The BaroSense products and procedures create a safe, simple, effective and reversible alternative to the surgical treatment of obesity. BaroSense offers a less invasive approach to assist those people who want to get more out of lifestyle change programs, and who wish to avoid extensive and irreversible surgical procedures.

Mimetogen Pharmaceuticals Inc. is a pharmaceuticals company based out of 1000 de La Gauchetiare Street West, Suite 900, Quebec, Montreal, Quebec, Canada.